WebHoverink Biotechnologies, Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Hoverink Biotechnologies, Inc.. Web27 de set. de 2024 · CENTURY CITY, CA / ACCESSWIRE / September 26, 2024 / Hoverink Biotechnologies, Inc., today announced that they have plans to develop and …
Debbie Mae Carter, Hoverink Biotechnologies Inc: Profile and …
WebCyrus Sajna is Interim CEO/CFO at Hoverink Biotechnologies Inc. See Cyrus Sajna's compensation, career history, education, & memberships. Web26 de set. de 2024 · Trademark Overview. On Wednesday, September 26, 2024, a trademark application was filed for KAIYADRU with the United States Patent and Trademark Office. The USPTO has given the KAIYADRU trademark a serial number of 88133141. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE … first stage of atherosclerosis
Cyrus Sajna - U.S. House of Representatives …
Web11 de abr. de 2024 · -- Adaptive Biotechnologies said Wednesday it has entered a translational collaboration with Takeda Pharmaceutical to use its clonoSEQ assay to assess minimal residual disease in patients with... April 12, 2024 Web23 de jan. de 2024 · Los Angeles, Jan. 23, 2024 -- Hoverink Biotechnologies announced today that CEO Debbie Mae Carter will step down and will be succeeded by Cyrus Sajna as CEO and CFO of the company. ... WebOur mission is to improve the lives of patients who suffer from rare diseases for which there are... Los Angeles, Califórnia, Estados Unidos 90067 first stage of cancer treatment